Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Declares Quarterly Dividend of $0.94

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Wednesday, April 29th. Stockholders of record on Wednesday, May 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, June 4th. This represents a c) dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $42.14 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $45.41 during mid-day trading on Wednesday, reaching $686.36. 1,831,580 shares of the company’s stock traded hands, compared to its average volume of 741,458. The firm has a 50 day moving average price of $760.43 and a two-hundred day moving average price of $735.71. The firm has a market capitalization of $72.56 billion, a PE ratio of 16.51, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $9.10 by $0.37. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.45 billion. During the same quarter last year, the business earned $8.22 EPS. The firm’s revenue was up 19.0% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals will post 35.98 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.